查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1871986

口服蛋白质和胜肽：全球市场份额和排名、总收入和需求预测（2025-2031年）

Oral Proteins and Peptides - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 87 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球口服蛋白质和胜肽市场规模估计为 23.46 亿美元，预计到 2031 年将达到 63.55 亿美元，在预测期（2025-2031 年）内以 15.3% 的复合年增长率增长。

本报告对口服蛋白质和胜肽领域近期的关税调整和国际战略反制措施进行了全面评估，重点关注跨境产业基地、资本配置模式、区域经济相互依存关係和供应链重组。

多肽和蛋白质药物是指由多肽和蛋白质物质製成的生物製剂，用于预防、治疗和诊断。多肽是由α-胺基酸连接成胜肽链的化合物，也是蛋白质降解的中间产物。蛋白质是由多条多肽链以特定的空间结构相互缠绕而成。多肽是透过水解高分子量蛋白质产生的。这些药物属于生化製剂，对其储存和运输环境有较严格的要求。

随着给药技术的进步，口服替代注射已成为新的趋势，提高了患者的依从性，促进了市场成长。

治疗糖尿病和发炎性肠道疾病等慢性疾病的口服蛋白质和胜肽类药物的需求持续成长。

奈米递送系统和酵素抑制封装技术不断成熟，解决了消化降解问题，并扩大了产品开发的范围。

世界各地的许多生物製药公司正在推动临床试验和合作开发，以加速商业化进程。

儘管面临监管挑战和成本压力，口服蛋白质和胜肽市场仍然被认为是一个具有巨大潜力的蓝海产业。

本报告旨在按地区/国家、类型和应用对全球口服蛋白质和胜肽市场进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

本报告以2024年为基准年，对口服蛋白质和胜肽的市场规模、估计值和预测进行了阐述，并以销售量（公斤）和收入（百万美元）为单位，涵盖了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定口服蛋白质和胜肽的业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Ironwood & Allergan（AbbVie）
  • Novo Nordisk
  • Synergy Pharmaceuticals（Salix）
  • Novartis
  • Chiasma（Amryt Pharma）

按类型分類的细分市场

  • 利那洛肽
  • 胰岛素
  • Plecanatide
  • Cyclosporine
  • Octreotide

应用领域

  • 胃/消化系统疾病
  • 骨骼疾病
  • 糖尿病
  • 荷尔蒙失调

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Oral Proteins and Peptides was estimated to be worth US$ 2346 million in 2024 and is forecast to a readjusted size of US$ 6355 million by 2031 with a CAGR of 15.3% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Oral Proteins and Peptides cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Polypeptide and protein drugs refer to the biological drugs of polypeptide and protein substances used for prevention, treatment and diagnosis. Polypeptide is a compound formed by linking a-amino acids together with a peptide chain, and it is also an intermediate product of proteolysis. N polypeptide chains are entangled in a certain spatial structure to form a protein. The hydrolysis of macromolecular proteins produces polypeptides. Such drugs are biochemical preparations and have relatively strict requirements on storage and transportation environment.

With the breakthrough of delivery technology, oral alternatives to injections have become a new trend, improving patient compliance and driving market growth.

The demand for oral protein and peptide drugs for the treatment of chronic diseases (such as diabetes and inflammatory bowel disease) continues to rise.

Nano-delivery systems and enzyme inhibition encapsulation technologies continue to mature, solving gastrointestinal degradation problems and expanding product development space.

Many biopharmaceutical companies around the world are advancing clinical trials and cooperative development to accelerate the commercialization process.

Despite regulatory challenges and cost pressures, the oral protein/peptide market is still seen as a high-potential blue ocean track.

This report aims to provide a comprehensive presentation of the global market for Oral Proteins and Peptides, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Oral Proteins and Peptides by region & country, by Type, and by Application.

The Oral Proteins and Peptides market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Proteins and Peptides.

Market Segmentation

By Company

  • Ironwood & Allergan (AbbVie)
  • Novo Nordisk
  • Synergy Pharmaceuticals (Salix)
  • Novartis
  • Chiasma (Amryt Pharma)

Segment by Type

  • Linaclotide
  • Insulin
  • Plecanatide
  • Cyclosporine
  • Octreotide

Segment by Application

  • Gastric & Digestive Disorders
  • Bone Diseases
  • Diabetes
  • Hormonal Disorders

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oral Proteins and Peptides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Oral Proteins and Peptides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Oral Proteins and Peptides in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Oral Proteins and Peptides Product Introduction
  • 1.2 Global Oral Proteins and Peptides Market Size Forecast
    • 1.2.1 Global Oral Proteins and Peptides Sales Value (2020-2031)
    • 1.2.2 Global Oral Proteins and Peptides Sales Volume (2020-2031)
    • 1.2.3 Global Oral Proteins and Peptides Sales Price (2020-2031)
  • 1.3 Oral Proteins and Peptides Market Trends & Drivers
    • 1.3.1 Oral Proteins and Peptides Industry Trends
    • 1.3.2 Oral Proteins and Peptides Market Drivers & Opportunity
    • 1.3.3 Oral Proteins and Peptides Market Challenges
    • 1.3.4 Oral Proteins and Peptides Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Oral Proteins and Peptides Players Revenue Ranking (2024)
  • 2.2 Global Oral Proteins and Peptides Revenue by Company (2020-2025)
  • 2.3 Global Oral Proteins and Peptides Players Sales Volume Ranking (2024)
  • 2.4 Global Oral Proteins and Peptides Sales Volume by Company Players (2020-2025)
  • 2.5 Global Oral Proteins and Peptides Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Oral Proteins and Peptides Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Oral Proteins and Peptides Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Oral Proteins and Peptides
  • 2.9 Oral Proteins and Peptides Market Competitive Analysis
    • 2.9.1 Oral Proteins and Peptides Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Oral Proteins and Peptides Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Proteins and Peptides as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Linaclotide
    • 3.1.2 Insulin
    • 3.1.3 Plecanatide
    • 3.1.4 Cyclosporine
    • 3.1.5 Octreotide
  • 3.2 Global Oral Proteins and Peptides Sales Value by Type
    • 3.2.1 Global Oral Proteins and Peptides Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Oral Proteins and Peptides Sales Value, by Type (2020-2031)
    • 3.2.3 Global Oral Proteins and Peptides Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Oral Proteins and Peptides Sales Volume by Type
    • 3.3.1 Global Oral Proteins and Peptides Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Oral Proteins and Peptides Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Oral Proteins and Peptides Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Oral Proteins and Peptides Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Gastric & Digestive Disorders
    • 4.1.2 Bone Diseases
    • 4.1.3 Diabetes
    • 4.1.4 Hormonal Disorders
  • 4.2 Global Oral Proteins and Peptides Sales Value by Application
    • 4.2.1 Global Oral Proteins and Peptides Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Oral Proteins and Peptides Sales Value, by Application (2020-2031)
    • 4.2.3 Global Oral Proteins and Peptides Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Oral Proteins and Peptides Sales Volume by Application
    • 4.3.1 Global Oral Proteins and Peptides Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Oral Proteins and Peptides Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Oral Proteins and Peptides Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Oral Proteins and Peptides Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Oral Proteins and Peptides Sales Value by Region
    • 5.1.1 Global Oral Proteins and Peptides Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Oral Proteins and Peptides Sales Value by Region (2020-2025)
    • 5.1.3 Global Oral Proteins and Peptides Sales Value by Region (2026-2031)
    • 5.1.4 Global Oral Proteins and Peptides Sales Value by Region (%), (2020-2031)
  • 5.2 Global Oral Proteins and Peptides Sales Volume by Region
    • 5.2.1 Global Oral Proteins and Peptides Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Oral Proteins and Peptides Sales Volume by Region (2020-2025)
    • 5.2.3 Global Oral Proteins and Peptides Sales Volume by Region (2026-2031)
    • 5.2.4 Global Oral Proteins and Peptides Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Oral Proteins and Peptides Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.4.2 North America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.5.2 Europe Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Oral Proteins and Peptides Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.7.2 South America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Oral Proteins and Peptides Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Oral Proteins and Peptides Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Oral Proteins and Peptides Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Oral Proteins and Peptides Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.3.2 United States Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.4.2 Europe Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.5.2 China Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.6.2 Japan Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.7.2 South Korea Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Oral Proteins and Peptides Sales Value, 2020-2031
    • 6.9.2 India Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Oral Proteins and Peptides Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Ironwood & Allergan (AbbVie)
    • 7.1.1 Ironwood & Allergan (AbbVie) Company Information
    • 7.1.2 Ironwood & Allergan (AbbVie) Introduction and Business Overview
    • 7.1.3 Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Product Offerings
    • 7.1.5 Ironwood & Allergan (AbbVie) Recent Development
  • 7.2 Novo Nordisk
    • 7.2.1 Novo Nordisk Company Information
    • 7.2.2 Novo Nordisk Introduction and Business Overview
    • 7.2.3 Novo Nordisk Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Novo Nordisk Oral Proteins and Peptides Product Offerings
    • 7.2.5 Novo Nordisk Recent Development
  • 7.3 Synergy Pharmaceuticals (Salix)
    • 7.3.1 Synergy Pharmaceuticals (Salix) Company Information
    • 7.3.2 Synergy Pharmaceuticals (Salix) Introduction and Business Overview
    • 7.3.3 Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Product Offerings
    • 7.3.5 Synergy Pharmaceuticals (Salix) Recent Development
  • 7.4 Novartis
    • 7.4.1 Novartis Company Information
    • 7.4.2 Novartis Introduction and Business Overview
    • 7.4.3 Novartis Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Novartis Oral Proteins and Peptides Product Offerings
    • 7.4.5 Novartis Recent Development
  • 7.5 Chiasma (Amryt Pharma)
    • 7.5.1 Chiasma (Amryt Pharma) Company Information
    • 7.5.2 Chiasma (Amryt Pharma) Introduction and Business Overview
    • 7.5.3 Chiasma (Amryt Pharma) Oral Proteins and Peptides Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Chiasma (Amryt Pharma) Oral Proteins and Peptides Product Offerings
    • 7.5.5 Chiasma (Amryt Pharma) Recent Development

8 Industry Chain Analysis

  • 8.1 Oral Proteins and Peptides Industrial Chain
  • 8.2 Oral Proteins and Peptides Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Oral Proteins and Peptides Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Oral Proteins and Peptides Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Oral Proteins and Peptides Market Trends
  • Table 2. Oral Proteins and Peptides Market Drivers & Opportunity
  • Table 3. Oral Proteins and Peptides Market Challenges
  • Table 4. Oral Proteins and Peptides Market Restraints
  • Table 5. Global Oral Proteins and Peptides Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Oral Proteins and Peptides Revenue Market Share by Company (2020-2025)
  • Table 7. Global Oral Proteins and Peptides Sales Volume by Company (2020-2025) & (Kg)
  • Table 8. Global Oral Proteins and Peptides Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Oral Proteins and Peptides Price by Company (2020-2025) & (US$/kg)
  • Table 10. Key Manufacturers Oral Proteins and Peptides Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Oral Proteins and Peptides Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Oral Proteins and Peptides
  • Table 13. Global Oral Proteins and Peptides Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Proteins and Peptides as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Oral Proteins and Peptides Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Oral Proteins and Peptides Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Oral Proteins and Peptides Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Oral Proteins and Peptides Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Oral Proteins and Peptides Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Oral Proteins and Peptides Sales Volume by Type: 2020 VS 2024 VS 2031 (Kg)
  • Table 22. Global Oral Proteins and Peptides Sales Volume by Type (2020-2025) & (Kg)
  • Table 23. Global Oral Proteins and Peptides Sales Volume by Type (2026-2031) & (Kg)
  • Table 24. Global Oral Proteins and Peptides Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Oral Proteins and Peptides Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Oral Proteins and Peptides Price by Type (2020-2025) & (US$/kg)
  • Table 27. Global Oral Proteins and Peptides Price by Type (2026-2031) & (US$/kg)
  • Table 28. Global Oral Proteins and Peptides Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Oral Proteins and Peptides Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Oral Proteins and Peptides Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Oral Proteins and Peptides Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Oral Proteins and Peptides Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Oral Proteins and Peptides Sales Volume by Application: 2020 VS 2024 VS 2031 (Kg)
  • Table 34. Global Oral Proteins and Peptides Sales Volume by Application (2020-2025) & (Kg)
  • Table 35. Global Oral Proteins and Peptides Sales Volume by Application (2026-2031) & (Kg)
  • Table 36. Global Oral Proteins and Peptides Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Oral Proteins and Peptides Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Oral Proteins and Peptides Price by Application (2020-2025) & (US$/kg)
  • Table 39. Global Oral Proteins and Peptides Price by Application (2026-2031) & (US$/kg)
  • Table 40. Global Oral Proteins and Peptides Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Oral Proteins and Peptides Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Oral Proteins and Peptides Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Oral Proteins and Peptides Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Oral Proteins and Peptides Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Oral Proteins and Peptides Sales Volume by Region (Kg): 2020 VS 2024 VS 2031
  • Table 46. Global Oral Proteins and Peptides Sales Volume by Region (2020-2025) & (Kg)
  • Table 47. Global Oral Proteins and Peptides Sales Volume by Region (2026-2031) & (Kg)
  • Table 48. Global Oral Proteins and Peptides Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Oral Proteins and Peptides Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Oral Proteins and Peptides Average Price by Region (2020-2025) & (US$/kg)
  • Table 51. Global Oral Proteins and Peptides Average Price by Region (2026-2031) & (US$/kg)
  • Table 52. Key Countries/Regions Oral Proteins and Peptides Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Oral Proteins and Peptides Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Oral Proteins and Peptides Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Oral Proteins and Peptides Sales Volume, (2020-2025) & (Kg)
  • Table 56. Key Countries/Regions Oral Proteins and Peptides Sales Volume, (2026-2031) & (Kg)
  • Table 57. Ironwood & Allergan (AbbVie) Company Information
  • Table 58. Ironwood & Allergan (AbbVie) Introduction and Business Overview
  • Table 59. Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 60. Ironwood & Allergan (AbbVie) Oral Proteins and Peptides Product Offerings
  • Table 61. Ironwood & Allergan (AbbVie) Recent Development
  • Table 62. Novo Nordisk Company Information
  • Table 63. Novo Nordisk Introduction and Business Overview
  • Table 64. Novo Nordisk Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 65. Novo Nordisk Oral Proteins and Peptides Product Offerings
  • Table 66. Novo Nordisk Recent Development
  • Table 67. Synergy Pharmaceuticals (Salix) Company Information
  • Table 68. Synergy Pharmaceuticals (Salix) Introduction and Business Overview
  • Table 69. Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 70. Synergy Pharmaceuticals (Salix) Oral Proteins and Peptides Product Offerings
  • Table 71. Synergy Pharmaceuticals (Salix) Recent Development
  • Table 72. Novartis Company Information
  • Table 73. Novartis Introduction and Business Overview
  • Table 74. Novartis Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 75. Novartis Oral Proteins and Peptides Product Offerings
  • Table 76. Novartis Recent Development
  • Table 77. Chiasma (Amryt Pharma) Company Information
  • Table 78. Chiasma (Amryt Pharma) Introduction and Business Overview
  • Table 79. Chiasma (Amryt Pharma) Oral Proteins and Peptides Sales (Kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
  • Table 80. Chiasma (Amryt Pharma) Oral Proteins and Peptides Product Offerings
  • Table 81. Chiasma (Amryt Pharma) Recent Development
  • Table 82. Key Raw Materials Lists
  • Table 83. Raw Materials Key Suppliers Lists
  • Table 84. Oral Proteins and Peptides Downstream Customers
  • Table 85. Oral Proteins and Peptides Distributors List
  • Table 86. Research Programs/Design for This Report
  • Table 87. Key Data Information from Secondary Sources
  • Table 88. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Oral Proteins and Peptides Product Picture
  • Figure 2. Global Oral Proteins and Peptides Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Oral Proteins and Peptides Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Oral Proteins and Peptides Sales Volume (2020-2031) & (Kg)
  • Figure 5. Global Oral Proteins and Peptides Sales Price (2020-2031) & (US$/kg)
  • Figure 6. Oral Proteins and Peptides Report Years Considered
  • Figure 7. Global Oral Proteins and Peptides Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Oral Proteins and Peptides Players Sales Volume Ranking (2024) & (Kg)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Oral Proteins and Peptides Revenue in 2024
  • Figure 10. Oral Proteins and Peptides Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Linaclotide Picture
  • Figure 12. Insulin Picture
  • Figure 13. Plecanatide Picture
  • Figure 14. Cyclosporine Picture
  • Figure 15. Octreotide Picture
  • Figure 16. Global Oral Proteins and Peptides Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Oral Proteins and Peptides Sales Value Market Share by Type, 2024 & 2031
  • Figure 18. Global Oral Proteins and Peptides Sales Volume by Type (2020 VS 2024 VS 2031) & (Kg)
  • Figure 19. Global Oral Proteins and Peptides Sales Volume Market Share by Type, 2024 & 2031
  • Figure 20. Global Oral Proteins and Peptides Price by Type (2020-2031) & (US$/kg)
  • Figure 21. Product Picture of Gastric & Digestive Disorders
  • Figure 22. Product Picture of Bone Diseases
  • Figure 23. Product Picture of Diabetes
  • Figure 24. Product Picture of Hormonal Disorders
  • Figure 25. Global Oral Proteins and Peptides Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 26. Global Oral Proteins and Peptides Sales Value Market Share by Application, 2024 & 2031
  • Figure 27. Global Oral Proteins and Peptides Sales Volume by Application (2020 VS 2024 VS 2031) & (Kg)
  • Figure 28. Global Oral Proteins and Peptides Sales Volume Market Share by Application, 2024 & 2031
  • Figure 29. Global Oral Proteins and Peptides Price by Application (2020-2031) & (US$/kg)
  • Figure 30. North America Oral Proteins and Peptides Sales Value (2020-2031) & (US$ Million)
  • Figure 31. North America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • Figure 32. Europe Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Asia Pacific Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Asia Pacific Oral Proteins and Peptides Sales Value by Region (%), 2024 VS 2031
  • Figure 36. South America Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. South America Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • Figure 38. Middle East & Africa Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Middle East & Africa Oral Proteins and Peptides Sales Value by Country (%), 2024 VS 2031
  • Figure 40. Key Countries/Regions Oral Proteins and Peptides Sales Value (%), (2020-2031)
  • Figure 41. Key Countries/Regions Oral Proteins and Peptides Sales Volume (%), (2020-2031)
  • Figure 42. United States Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. United States Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 44. United States Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Europe Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Europe Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Europe Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 48. China Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. China Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 50. China Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Japan Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. Japan Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 53. Japan Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 54. South Korea Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. South Korea Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 56. South Korea Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 57. Southeast Asia Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. Southeast Asia Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 59. Southeast Asia Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 60. India Oral Proteins and Peptides Sales Value, (2020-2031) & (US$ Million)
  • Figure 61. India Oral Proteins and Peptides Sales Value by Type (%), 2024 VS 2031
  • Figure 62. India Oral Proteins and Peptides Sales Value by Application (%), 2024 VS 2031
  • Figure 63. Oral Proteins and Peptides Industrial Chain
  • Figure 64. Oral Proteins and Peptides Manufacturing Cost Structure
  • Figure 65. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 66. Bottom-up and Top-down Approaches for This Report
  • Figure 67. Data Triangulation
  • Figure 68. Key Executives Interviewed